Leporello έγραψε: ↑25 Νοέμ 2021, 18:28
Αρίστος έγραψε: ↑25 Νοέμ 2021, 18:16
Aπο τις αρχες του αιωνα μας το Ιδρυμα Γκειτς αγοραζει μετοχες σε 9 φαρμακευτικους κολοσσους και χρηματοδοτει προγραμματα τους, αναμεσα τους φυσικα ειναι και η Pfizer.
Bill Gates, the Microsoft founder and a recent global health campaigner, has invested $205m in nine large pharmaceutical companies.
The investment has been made through the Bill and Melinda Gates Foundation, the largest charitable body in the US with an endowment of $24bn (£16.5bn). It has become a significant force in international health issues and contributed $555m to programmes last year alone.
The decision to take stakes in individual firms appears to be a shift in strategy, and for the first time aligns the charity's interests with those of the drugs firms. The foundation had eschewed equity investments and held shares in just two companies - cable firm Cox Communications and Waste Management. Now it has ploughed $76.9m into Merck shares, $37.3m into Pfizer and $29.7m into Johnson & Johnson.
Mr Gates has already built some ties with the drugs industry. Merck chief executive Raymond Gilmartin joined the Microsoft board last year while Mr Gates helped Merck with AIDS programmes in Botswana - much of the foundation's focus has been on improving health in the developing world.
Investment in drugs firms could leave the foundation open to criticism. A representative sits on the board of the Global Alliance for Vaccines and Immunisations which buys vaccines from some of the pharmaceutical firms in which the foundation now holds shares.
A spokesman for the foundation said the investments were independent of the charitable programmes.
Mr Gates' belief in the importance of intellectual property protection for drugs in the developing world as a means of encouraging investment is also controversial.
The foundation was created in 2000 through the merger of the Gates Learning Foundation and the William H Gates Foundation and is chaired by Bill Gates senior.
https://www.theguardian.com/business/20 ... .microsoft
Кαι λοιπόν; Οπως είπα, κι'εγώ είμαι μέτοχος στην ΔΕΗ. Μάλιστα, το ποσό που έχω επενδύσει ανάλογα με την περιουσία μου, είναι μεγαλύτερο από εκείνο που έχει επενδύσει ο Gates στην Pfizer. Το συμφέρον μου μάλιστα είναι να ανέβη η τιμή του ρεύματος, γιατί αυτά που θα χάσω πληρώνοντας υψηλότερο λογαριασμό θα είναι πολύ λιγότερα απ'όσα θα κερδίσω από την άνοδο τής μετοχής τής ΔΕΗ.
Ο δε Gates έχει επενδύσει μόλις πριν 15 μέρες $90 εκατομμύρια (σχεδόν τριπλάσια απ'όσα έχει επενδύσει στην Pfizer) στην Inventprise, ανταγωνιστική τής Pfizer. Και βέβαια, $37 εκατομμύρια, τόσο γιά τα δεδομένα του Gates, όσο και γιά τα δεδομένα τής Pfizer είναι αστείο ποσόν. Είναι λιγότερα απ'όσα επένδυσε (τρόπος του λέγειν) ο Γιαννακόπουλος στον Παναθηναϊκό.
Ελα παππου μου να σου δειξω τα αμπελοχωραφα σου.
Ο Μπιλ σχεδον καθε χρονο αγοραζει μετοχες και επενδυει τα λεφτα του σε ερευνητικα προγραμματα των φαρμακευτικων κολοσσων. Δεν εκανε μια αγορα μετοχων το 2002 και τερμα. Κανει βεβαια πολυ περισσοτερα απο αυτα καθως ειναι ο εκπροσωπος του λομπυ των φαρμακευτικων στον ΠΟΥ.
Και τωρα τσιμπα το καθημερινο τρομπονι που ζηταει ο οργανισμος σου.
4 Coronavirus Vaccine Stocks the Bill & Melinda Gates Foundation Is Betting OnPfizer
Bill Gates recently stated that he views Pfizer (NYSE:PFE) as the leader in the coronavirus vaccine race. In a CNBC interview, he said, "The only vaccine that, if everything went perfectly, might seek the emergency use license by the end of October, would be Pfizer."
The Gates Foundation also owns shares of the big drugmaker. However, this investment wasn't initiated because of Pfizer's coronavirus program. Actually, the foundation first bought a stake in Pfizer back in 2002 with the stated intention of "expand[ing] access to the pharmaceutical company's all-in-one injectable contraceptive, Sayana Press, giving women in the developing world an affordable option."
Gates is probably correct in assessing Pfizer as the coronavirus vaccine leader. The company expects to report initial results next month from a late-stage study of BNT162b2, the COVID-19 vaccine candidate that it's developing with BioNTech (NASDAQ:BNTX). If all goes well, BNT162b2 could very well become the first coronavirus vaccine available to Americans.
BioNTech
It's not surprising that the Bill & Melinda Gates Foundation also owns shares of BioNTech. Again, though, the nonprofit foundation didn't invest in the German biotech stock because of its coronavirus program.
The Gates Foundation first bought a position in BioNTech in September 2019, well before the COVID-19 pandemic hit. It invested $55 million in the biotech, with the potential for total funding to reach $100 million. The foundation's goal with this investment was to work with BioNTech to develop vaccines and immunotherapies for preventing HIV and tuberculosis (TB) infection.
BioNTech began developing its BNT162 COVID-19 vaccine program earlier this year. It had already made significant progress with this program when it announced a partnership with Pfizer in March.
CureVac
BioNTech wasn't the first German biotech to attract the attention of the Gates Foundation. In 2015, the foundation committed to investing $52 million in CureVac (NASDAQ:CVAC). In addition, the Gates Foundation agreed to provide separate funding for several projects to develop vaccines based on CureVac's messenger RNA (mRNA) platform.
CureVac listed its shares on the Nasdaq stock exchange in August 2020. The company is currently evaluating its mRNA COVID-19 vaccine in early stage clinical studies.
Vir Biotechnology
The Gates Foundation was one of the lead investors in Vir Biotechnology (NASDAQ:VIR) at the biotech's launch in late 2016 and early 2017. The foundation's goal with its position in Vir was to "support the development of affordable and accessible HIV and TB prophylactic vaccine programs, and support the development of a new partner in the infectious disease space."
Vir's pipeline now includes several coronavirus-focused programs. The company recently began a phase 2/3 clinical study with its partner, GlaxoSmithKline, evaluating an antibody therapy targeting COVID-19. Vir expects to initiate a phase 2 study of another COVID-19 antibody therapy, VIR-7832, later this year. VIR-7832 could potentially be used to treat COVID-19 and as a vaccine to prevent infection. In addition, the biotech is conducting preclinical studies of an inhaled therapy targeting COVID-19.
https://www.fool.com/investing/2020/09/ ... inda-gate/
.